Peter Lynch fit · Growth at a reasonable price (GARP)
Is Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) a Peter Lynch Stock?
Strong GARP candidate — growth at a reasonable price.
72/100
BLikely Lynch stock
5/6 criteria passed
Peter Lynch's Criteria, Applied to AMRX
PEG ≤ 1.0
key—
EPS CAGR ≥ 15%
key37.4%
Revenue CAGR ≥ 10%
37.6%
Net margin > 0
0.2%
How AMRX Scores on Other Strategies
Live Financial Snapshot
Market cap
$4.21B
P/E (TTM)
-
ROIC (TTM)
9.19%
Gross margin
36.76%
Frequently Asked Questions
What is AMRX's Peter Lynch fit score?
AMRX scores 72/100 on our Peter Lynch fit engine — grade B. Strong GARP candidate — growth at a reasonable price.
Does Peter Lynch actually own AMRX?
Our score is computed from financial fundamentals against Peter Lynch's published criteria. We don't claim that Peter Lynch personally owns or recommends AMRX.
How often is this score updated?
AMRX's Peter Lynch fit score is recomputed daily from the latest TTM financials.
Educational tool, not investment advice. Scores are computed from publicly-available financial data against published investing-strategy criteria. We do not claim that Peter Lynch personally owns or recommends AMRX.